Journal article

B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice

Teja Devarakonda, Adolfo G Mauro, Geronimo Guzman, Sahak Hovsepian, Chad Cain, Anindita Das, Praveen Praveen, Mohammed Akhter Hossain, Fadi N Salloum

JOURNAL OF THE AMERICAN HEART ASSOCIATION | WILEY | Published : 2020

Abstract

Background Human relaxin-2 is a peptide hormone capable of pleiotropic effects in several organ systems. Its recombinant formulation (serelaxin) has been demonstrated to reduce infarct size and prevent excessive scar formation in animal models of cardiac ischemia-reperfusion injury. B7-33, a synthetically designed peptide analogous to B-chain of relaxin-2, invokes signaling at relaxin family peptide receptor 1 (cognate receptor for relaxin-2) by preferentially phosphorylating the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2. We sought to investigate the effects of B7-33 treatment post ischemia-reperfusion injury in mice. Methods and Results Adult male CD1 mice w..

View full abstract

Grants

Awarded by American Heart Association


Awarded by National Health and Medical Research Council Australia


Awarded by National Institutes of Health


Funding Acknowledgements

This study was supported by the American Heart Association (18PRE33990001) and the Wright Center for Clinical and Translational Research Center (Wright Scholar) to Dr Devarakonda, National Health and Medical Research Council Australia (GNT1122170) to Dr Hossain, and the National Institutes of Health (R01HL142281, R21AG053654, and R01HL133167) to Dr Salloum.